SHSE:603127's Forward Dividend Yield % is ranked better than 56.34% of 71
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.84
vs SHSE:603127: 2.21
During the past 12 months, Joinn Laboratories (China) Co's average Dividends Per Share Growth Rate was 55.60% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 65.00% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 60.00% per year.
During the past 12 years, the highest 3-Year average Dividends Per Share Growth Rate of Joinn Laboratories (China) Co was 66.20% per year. The lowest was 47.40% per year. And the median was 65.00% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co's Forward Dividend Yield % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Forward Dividend Yield % falls into.
Joinn Laboratories (China) Co Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Joinn Laboratories (China) Co Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
CNY 0.400000
2023-07-25
2023-07-24
2023-07-25
Cash Dividend
annually
CNY:CNY 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Joinn Laboratories (China) Co Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Joinn Laboratories (China) Co (SHSE:603127) Business Description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Joinn Laboratories (China) Co (SHSE:603127) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:603127 has been successfully added to your